An ongoing Phase III trial of Genentech, Inc. 's Tecentriq (atezolizumab) in patients who experienced early recurrence of triple-negative breast cancer after prior therapy could provide a pathway to confirming the PD-L1 inhibitor’s benefit in first-line TNBC, a current accelerated approval indication facing the threat of withdrawal.
On 27 April, the Food and Drug Administration’s Oncologic Drugs Advisory Committee will kick off three days of meetings on PD-1/L-1 inhibitor accelerated approval indications that have failed their confirmatory...
First up to bat is Genentech, which is seeking to retain Tecentriq’s indication for use in combination with protein-bound paclitaxel for treatment of patients with unresectable locally advanced or metastatic...